201 BROOKLINE AVENUE, BOSTON, MA
Appoints Robert Azelby to Board of Directors
Tango Therapeutics Enters Underwriting Agreement for $30.00 Offering
Investor Presentation
2026 Annual Meeting of Stockholders Held for Tango Therapeutics, Inc.
Reports First Quarter 2026 Financial Results and Provides Business Highlights
CFO Departure - Daniella Beckman Steps Down at Tango Therapeutics
Annual Report to Security Holders
Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Q1
FY 2025
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus